Top 5 Companies Developing Tumor Biomarker Testing Solutions

Published: April 2026

Tumor biomarkers are proteins, enzymes, antigens, or genetic material that may indicate the presence of cancer. Tumor markers play an essential role in diagnosing various types of cancer, identifying the stage of cancer, estimating cancer prognosis, and determining effective treatment options for cancers. Tumor biomarkers can be found in the blood, urine, stool, tumors, or other tissues or bodily fluids of cancer patients. It is worth highlighting that genomic biomarkers are being used as tumor markers.

Common types of tumor biomarkers include Prostate-Specific Antigen (PSA), Prostatic acid phosphatase (PAP), Carcinoembryonic antigen (CEA), Alpha-fetoprotein (AFP), Human chorionic gonadotropin (HCG), Lactate dehydrogenase (LDH), Neuron-specific enolase (NSE), CA 125, CA 19-9, CA 15-3 and CA 27-29.

Roots Analysis has conducted an exhaustive study on Cancer Biomarkers Market featuring the current market landscape and future opportunities for companies engaged in developing cancer biomarker testing solutions, over a span of next 9 years.

Key Companies Developing Tumor Biomarker Testing Solutions:

Thermo Fisher Scientific
Integrated DNA Technologies
Illumina
Labcorp
Qiagen

The figure below highlights the key Companies Developing Tumor Biomarker Testing Solutions:

Top 5 Players to Watch Developing Tumor Biomarker Testing Solutions

Interested in exploring all ~77 players engaged in the cancer biomarkers market, along with their recent initiatives?

Access Detailed Insights

Discover Below the Details on Key Companies Developing Tumor Biomarker Testing Solutions

Let us dive deep into the details of the key companies developing tumor biomarker testing solutions. It is essential to note that the selection of key companies providing tumor biomarker testing solutions can differ substantially according to the defined criteria.

1. Thermo Fisher Scientific

Thermo Fisher Scientific stands as a leading provider of comprehensive tools for tumor biomarker development, featuring cutting-edge next-generation sequencing (NGS) platforms like Ion Torrent and Genexus, along with specialized assays such as the Oncomine series for rapid, multi-biomarker profiling in cancers including non-small cell lung cancer and breast cancer.

In June 2025, Thermo Fisher Scientific announced the launch of Orbitrap Astral Zoom mass spectrometer, for the identification of new biomarkers for early diagnosis and management of diseases.

To know more about cancer biomarkers and the companies providing cancer biomarker testing solutions, access full report.

2. Integrated DNA Technologies

Integrated DNA Technologies is a global genomics company, which is a part of Danaher Corporation founded in 1987. IDT empowers cancer research through its xGen™ portfolio and Archer™ NGS assay solutions, offering customizable, high-performance tools for biomarker discovery, validation, and clinical insights. Its key offerings include Targeted NGS Panels for detecting mutations, fusions, copy number variations, tumor mutational burden (TMB), microsatellite instability (MSI), and other genomic alterations in solid tumors and blood cancers.

Recent Development:

In Feburary 2026, Integrated DNA Technologies participated in Advances in Genome Biology and Technology (AGBT) 2026 meeting from February 23–26 in Florida with the aim to reveal its NGS innovation roadmap to accelerate the future of cancer research.

To know more about cancer biomarkers and the companies providing cancer biomarker testing solutions, access full report.

Request Sample Pages

3. Illumina

Illumina is a global leader in genomics and tumor biomarker development, known for its innovative next-generation sequencing (NGS) technologies that power the majority of tumor genomic profiling worldwide. Its key offerings include comprehensive genomic profiling solutions, such as the TruSight Oncology Comprehensive test, an FDA-approved in vitro diagnostic kit that interrogates over 500 genes in solid tumors. This single assay can simultaneously assess hundreds of clinically actionable biomarkers, including single nucleotide variants, insertions / deletions, copy number variations, tumor mutational burden and microsatellite instability.

Recent Development:

In February 2026, Illumina announced customer-led advancements in cancer research by utilizing its spatial transcriptomics, 5-base sequencing (for simultaneous methylation and variant detection), and proteomics technologies.

To know more about cancer biomarkers and the companies providing cancer biomarker testing solutions, access full report.

4. Labcorp

Labcorp is a leading global provider of clinical laboratory services and a major player in precision oncology, offering extensive diagnostic testing for tumor biomarkers. Through its dedicated Labcorp Oncology division, the company delivers a comprehensive portfolio of over 450 specialized oncology tests, including advanced genomic profiling, liquid biopsies, and companion diagnostics. Some of the examples include: OmniSeq® INSIGHT, Labcorp Plasma Complete™.

Recent Development:

In January 2026, Labcorp announced the expansion of its molecular residual disease portfolio designed to precisely detect cancer recurrence in patients.

To know more about cancer biomarkers and the companies providing cancer biomarker testing solutions, access full report.

5. QIAGEN

QIAGEN established in 1984 is a prominent global leader in molecular diagnostics and a key player in tumor biomarker solution development. It provides multiplexed tools for detecting, analyzing, and validating cancer biomarkers across solid tumors, blood cancers, and immuno-oncology. Its oncology portfolio includes advanced next-generation sequencing (NGS) technologies like the QIAseq xHYB series for comprehensive genomic profiling (CGP), covering over 700 genes to detect SNVs, indels, CNVs, MSI, TMB and HRD ideal for identifying actionable alterations in cancers such as lung, breast, and ovarian

Recent Development:

In Feburary 2026, Qiagen announced its participation in American Association for Cancer Research (AACR) Annual Meeting 2026 which will be held in San Diego on April 17–22 to highlight their QIAsymphony Connect, platform for automated clinical sample preparation.

To know more about cancer biomarkers and the companies providing cancer biomarker testing solutions, access full report.

What About Other Cancer Biomarkers Testing Solution Providers Around the World?

The above article features the key companies developing tumor biomarker testing solutions. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Review Market Landscape

Sources: